Compare Twilio Inc (TWLO) vs 10X Genomics Inc (TXG) Price & Performance

Twilio (TWLO) trades at $196.22, down 5.11% in the last session, as investors await Q2 2026 earnings on August 6. The stock shows a bullish technical signal with strong moving average support and oversold RSI conditions. Fundamentally, the company has delivered three consecutive earnings beats with revenue growth from $3.8B in 2022 to $5.1B in 2025, though profitability remains modest with a 1.96% net margin. Operating cash flow improved significantly to $1.0B in 2025, indicating stronger business execution.

The outlook remains positive with 77% analyst buy ratings and a $227.64 consensus price target representing 16% upside. Key opportunities include AI-powered communication growth and margin expansion, while risks center on high valuation multiples (P/E 311) and competitive pressures. The upcoming earnings report will be critical for validating the company's turnaround strategy.

TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.

The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.